Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 31;16:115. doi: 10.1186/s12974-019-1499-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 5 — Anti-CCL20 antibody significantly reduces RGC loss, microgliosis, Müller cell activation and CCL20 expression in the retina. a Representative immunofluorescence images showing RGC (H&E), Iba1 (red), GFAP (green), or CCL20 (bright field) immunoreactivity in the retina with or without anti-CCL20 antibody or isotype treatment 7 days after rTBI. Scale bar 100 μm. Inset high-magnification images showing CCL20 expression in the retinal ganglionic cells, scale bar 20 μm. Blue fluorescence shows DAPI. b–e Histograms showing average count of RGC (b), Iba1-positive cells (c), average fluorescence intensity of GFAP immunoreactivity (d), or CCL20 immunoreactivity (e) as quantitated by ImageJ. f CCL20 protein expression in the retina as estimated by Quantikine ELISA. *p < 0.01, **p < 0.001, ***p < 0.0001